Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
4,700
Employees4,700
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
4,700
Employees4,700

MRNA Key Statistics

Market cap
20.76B
Market cap20.76B
Price-Earnings ratio
-7.35
Price-Earnings ratio-7.35
Dividend yield
Dividend yield
Average volume
11.15M
Average volume11.15M
High today
$55.09
High today$55.09
Low today
$51.44
Low today$51.44
Open price
$54.31
Open price$54.31
Volume
6.58M
Volume6.58M
52 Week high
$59.55
52 Week high$59.55
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

The current Moderna(MRNA) stock price is $52.21, with a market capitalization of 20.76B. The stock trades at a price-to-earnings (P/E) ratio of -7.35.

On 2026-03-13, Moderna(MRNA) stock moved within a range of $51.44 to $55.09. With shares now at $52.21, the stock is trading +1.5% above its intraday low and -5.2% below the session's peak.

Trading volume for Moderna(MRNA) stock has reached 6.58M, versus its average volume of 11.15M.

The stock's 52-week range extends from a low of $22.28 to a high of $59.55.

The stock's 52-week range extends from a low of $22.28 to a high of $59.55.

MRNA News

Simply Wall St 1d
Moderna Valuation Questioned As mRNA Guidance And Flu Review Shift

A U.S. health advisory committee is reconsidering its previous position against recommending mRNA vaccines. This review comes shortly after the FDA reversed it...

Moderna Valuation Questioned As mRNA Guidance And Flu Review Shift
Simply Wall St 2d
Is It Too Early To Reassess Moderna After Its Strong 2024 Share Price Rally?

If you are wondering whether Moderna's current share price reflects its true worth, you are not alone. Many investors are asking the same question as the market...

Is It Too Early To Reassess Moderna After Its Strong 2024 Share Price Rally?
Simply Wall St 6d
Patent Truce on mRNA Delivery Might Change The Case For Investing In Moderna

In early March 2026, Genevant Sciences, Arbutus Biopharma and Moderna reached a global settlement of up to US$2.25 billion over alleged unauthorized use of lipi...

Patent Truce on mRNA Delivery Might Change The Case For Investing In Moderna

Analyst ratings

73%

of 26 ratings
Buy
11.5%
Hold
73.1%
Sell
15.4%

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.